Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has received an average recommendation of “Hold” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.5556.

Several equities analysts recently commented on the company. JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday. Morgan Stanley raised their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Investors Research Corp boosted its position in shares of Pfizer by 1.2% in the 2nd quarter. Investors Research Corp now owns 38,962 shares of the biopharmaceutical company’s stock valued at $938,000 after purchasing an additional 481 shares during the period. Tema ETFs LLC lifted its stake in Pfizer by 10.7% in the second quarter. Tema ETFs LLC now owns 103,378 shares of the biopharmaceutical company’s stock valued at $2,489,000 after buying an additional 10,005 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the last quarter. City Holding Co. grew its position in shares of Pfizer by 4.7% during the second quarter. City Holding Co. now owns 35,409 shares of the biopharmaceutical company’s stock worth $852,000 after acquiring an additional 1,580 shares during the last quarter. Finally, Charles Schwab Trust Co increased its holdings in shares of Pfizer by 66.1% in the 2nd quarter. Charles Schwab Trust Co now owns 16,129 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 6,419 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Pfizer Stock Down 0.1%

Shares of NYSE PFE traded down $0.04 during mid-day trading on Tuesday, hitting $24.21. The company had a trading volume of 27,476,453 shares, compared to its average volume of 47,734,172. The business’s 50-day simple moving average is $25.37 and its 200 day simple moving average is $26.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $138.01 billion, a PE ratio of 18.48 and a beta of 0.35. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm earned $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.